In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At ...

Follow the latest news updates on the Sean "Diddy" Combs trial. Defense hammers ex-assistant for posts supporting Combs after alleged assaults.

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

BEACON and Open-Label Extension Study Design and Data Summary: ...

Abatacept reduces the rate of progression to RA and improves the rate of remission in patients with palindromic rheumatism ...

Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ("Beacon Therapeutics" or "the Company"), a leading clinical-stage ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

Phase 2b data show olorofim effective against resistant IFD, including azole-resistant fungi, with a favourable safety profile.